Sirtex Medical US Holdings, Inc.
Global medical device company focused on minimally invasive liver-directed cancer therapies. Provides intra-arterial radiotherapeutic microspheres, clinician support programs, treatment-planning and dosimetry software, ordering/logistics services, practitioner training and clinical trial support to enable selective internal radiation therapy workflows.
Industries
Nr. of Employees
large (251-1000)
Sirtex Medical US Holdings, Inc.
Sirtex Medical Inc., 300 Unicorn Park Drive, Woburn MA 01801, United States
Products
Yttrium-90 resin microsphere therapeutic
Radiotherapeutic resin microspheres containing yttrium-90 for intra-arterial administration to treat unresectable primary and metastatic liver tumors.
Adaptable microsphere delivery system and accessory kits
Delivery system and accessory packs designed to allow controlled, visual and patient-tailored administration of microspheres, including preparation and delivery components.
Treatment-planning and dosimetry software for liver
Clinical software supporting liver and tumor segmentation, deformable registration and post-treatment dosimetry to assist activity prescription and treatment evaluation.
Degradable starch microspheres for chemoembolization (50 µm)
A degradable starch microsphere embolic agent intended for chemoembolization in the treatment of inoperable liver and lung tumors.
Yttrium-90 resin microsphere therapeutic
Radiotherapeutic resin microspheres containing yttrium-90 for intra-arterial administration to treat unresectable primary and metastatic liver tumors.
Adaptable microsphere delivery system and accessory kits
Delivery system and accessory packs designed to allow controlled, visual and patient-tailored administration of microspheres, including preparation and delivery components.
Treatment-planning and dosimetry software for liver
Clinical software supporting liver and tumor segmentation, deformable registration and post-treatment dosimetry to assist activity prescription and treatment evaluation.
Degradable starch microspheres for chemoembolization (50 µm)
A degradable starch microsphere embolic agent intended for chemoembolization in the treatment of inoperable liver and lung tumors.
Services
Online pre-determination intake, document submission, and reimbursement-team support to facilitate insurance authorization.
Program and workflow consultancy to coordinate order placement, mapping procedures and definitive treatment visits across sites.
Training and educational programs for physicians and center staff on handling, delivery and best practices for interventional radiotherapeutic therapies.
Online order forms, scheduling of delivery with calibration/activity timing and customer service confirmation.
Support for ongoing and planned clinical studies related to interventional radiotherapeutic therapies, including trial information and investigator resources.
Online pre-determination intake, document submission, and reimbursement-team support to facilitate insurance authorization.
Program and workflow consultancy to coordinate order placement, mapping procedures and definitive treatment visits across sites.
Training and educational programs for physicians and center staff on handling, delivery and best practices for interventional radiotherapeutic therapies.
Online order forms, scheduling of delivery with calibration/activity timing and customer service confirmation.
Support for ongoing and planned clinical studies related to interventional radiotherapeutic therapies, including trial information and investigator resources.
Expertise Areas
- Selective internal radiation therapy program implementation
- Radioembolization dosimetry and post-treatment dose quantification
- Interventional radiology and catheter-based intra-arterial delivery
- Liver segmentation, deformable registration and treatment-planning workflows
Key Technologies
- Yttrium-90 resin microspheres (intra-arterial radioembolization)
- Image-guided selective internal radiation therapy (SIRT)
- Voxel-based and partition-model dosimetry methods
- SPECT/CT and PET/CT imaging for quantitative assessment
News & Updates
International multidisciplinary consensus recommendations on personalized selective internal radiation therapy and dosimetry for primary and metastatic liver disease.
Published indication clarifying use of yttrium-90 resin microspheres for unresectable hepatocellular carcinoma and metastatic colorectal liver tumors in patients refractory or intolerant to chemotherapy (effective May 7, 2021).
International multidisciplinary consensus recommendations on personalized selective internal radiation therapy and dosimetry for primary and metastatic liver disease.
Published indication clarifying use of yttrium-90 resin microspheres for unresectable hepatocellular carcinoma and metastatic colorectal liver tumors in patients refractory or intolerant to chemotherapy (effective May 7, 2021).